Of mitochondrion and COVID-19

• Published in: Journal of enzyme inhibition and medicinal chemistry Vol. 36; no. 1; pp. 1258 - 1266
• Main Authors: Alfarouk, Khalid Omer, Alhoufie, Sari T. S., Hifny, Abdelhameed, Schwartz, Laurent, Alqahtani, Ali S., Ahmed, Samrein B. M., Alqahtani, Ali M., Alqahtani, Saad S., Muddathir, Abdel Khalig, Ali, Heyam, Bashir, Adil H. H., Ibrahim, Muntaser E., Greco, Maria Raffaella, Cardone, Rosa A., Harguindey, Salvador, Reshkin, Stephan Joel
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.01.2021; Taylor & Francis Group
• Subjects: Antiviral Agents - chemistry; Antiviral Agents - pharmacology; COVID-19; COVID-19 - metabolism; COVID-19 - pathology; COVID-19 Drug Treatment; cytokine storm; Humans; inflammation; Mitochondria - drug effects; Mitochondria - metabolism; Mitochondria - pathology; mitochondrion; Review; SARS-CoV-2 - drug effects; SARS-CoV-2 - pathogenicity; treatment; COVID-19; treatment; cytokine storm; inflammation; mitochondrion
• ISSN: 1475-6366; 1475-6374
• DOI: 10.1080/14756366.2021.1937144

COVID-19, a pandemic disease caused by a viral infection, is associated with a high mortality rate. Most of the signs and symptoms, e.g. cytokine storm, electrolytes imbalances, thromboembolism, etc., are related to mitochondrial dysfunction. Therefore, targeting mitochondrion will represent a more rational treatment of COVID-19. The current work outlines how COVID-19's signs and symptoms are related to the mitochondrion. Proper understanding of the underlying causes might enhance the opportunity to treat COVID-19.